<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical indications for palivizumab immunoprophylaxis against severe respiratory syncytial virus infections in infants</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical indications for palivizumab immunoprophylaxis against severe respiratory syncytial virus infections in infants</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical indications for palivizumab immunoprophylaxis against severe respiratory syncytial virus infections in infants</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup> <colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Population</td> <td class="subtitle1">Indications (only if nirsevimab is not available)</td> </tr> <tr> <td>Preterm infants with BPD*</td> <td> <ul> <li>&lt;12 months of age at the start of RSV season</li> <li>Age 12 through 23 months and required medical therapy (eg, supplemental oxygen, glucocorticoids, diuretics) for BPD within six months of the start of RSV season</li> </ul> </td> </tr> <tr> <td>Preterm infants without BPD</td> <td> <ul> <li>Infants born at &lt;29 weeks GA who are &lt;12 months of age at the start of the RSV season</li> <li>Preterm infants born at 29 to &lt;32 weeks GA who are &lt;12 months of age at the start of the RSV season and who have additional risk factors (eg, age &lt;4 months at peak RSV season, attending daycare, older sibling in the household, parental smoking)<sup>¶</sup></li> </ul> </td> </tr> <tr> <td>Infants with CHD</td> <td>Most likely to benefit: <ul class="decimal_heading"> <li>Infants &lt;12 months of age with acyanotic heart disease who are receiving medication to control heart failure and will require cardiac surgery</li> <li>Infants &lt;12 months of age with moderate to severe pulmonary hypertension</li> </ul> <p class="extra_spacing_top">May benefit:</p> <ul class="decimal_heading"> <li>Infants &lt;12 months of age with cyanotic heart disease (decisions should be made in consultation with the infant's cardiologist)</li> </ul> </td> </tr> <tr> <td>Other potential candidates<sup>Δ</sup></td> <td> <ul> <li>Infants and children &lt;2 years of age with primary immunodeficiency syndrome (eg, SCID) or significant immunosuppression (eg, heart or lung transplant or HCT)</li> <li>Infants &lt;12 months of age with severe neuromuscular disease</li> <li>Infants &lt;12 months of age with severe pulmonary disease (eg, TEF)</li> <li>Infants &lt;12 months of age with Down syndrome</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes our suggested indications for palivizumab in high-risk infants. <strong>NOTE:</strong> Palivizumab should only be used if nirsevimab is not available. In addition to immunoprophylaxis, other general measures to prevent RSV infection in high-risk infants include hand washing, practicing cough hygiene, avoidance of tobacco and other smoke, and restricting participation in childcare during RSV season (if possible). Refer to UpToDate's topic on RSV prevention for additional details, including a description of the evidence supporting the efficacy of palivizumab.</div><div class="graphic_footnotes"><p>RSV: respiratory syncytial virus; BPD: bronchopulmonary dysplasia; GA: gestational age; CHD: congenital heart disease; TEF: tracheoesophageal fistula; SCID: severe combined immunodeficiency; HCT: hematopoietic cell transplant.</p>
<p>* BPD is variably defined. For the purpose of this table, we define BPD as GA &lt;32 weeks and a requirement for supplementation oxygen for at least the first 28 days after birth.</p>
<p>¶ These risk factors plus out of pocket cost are taken into consideration on a case-by-case basis in consultation with the infant's caregiver(s).</p>
Δ Use of palivizumab in these patient populations is not standardized and evidence is limited.</div><div id="graphicVersion">Graphic 141499 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
